Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare reported standalone revenue from operations of Rs 442.9 crore for Q3 FY26, up 20.7% from Rs 366.9 crore in Q3 FY25. For the 9-month period, revenue grew 25.9% to Rs 1,331.8 crore versus Rs 1,057.4 crore a year ago. Net profit for Q3 stood at Rs 28.4 crore, down from Rs 39.6 crore in the year-ago quarter, while 9M net profit more than doubled to Rs 205.4 crore from Rs 106 crore, boosted by a Rs 43.2 crore exceptional gain (mainly reversal of subsidiary impairment). EBITDA for 9M was Rs 435.4 crore, up 21.6% YoY, with operating margin expanding to 21.5% from 17.5%. The board also approved a new ESOP 2026 scheme with a pool of 1.5 crore options and revised the Related Party Transaction Policy.
The strong 9M revenue and earnings growth, along with margin expansion, is a positive signal for shareholders, though Q3 profit dipped due to higher finance costs and lower other income. The long-pending IHH open offer concluded in November 2025, and ESOP 2026 may cause future dilution. The auditor's report is unmodified but draws attention to ongoing SFIO and Supreme Court-related matters, which remain key overhangs to monitor.